DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
FactSet - 1 Locker - 1 Foot Locker - 1 February's nonfarm - 1 Jerome Powell - 1 he's - 1 we'll - 1 MANU - 1
Top related locs:
U.S Asana ASAN Williams Washington United States
Top related orgs:
Nasdaq - 1 Dow Jones Industrial - 1 Costco - 1 Broadcom - 1 Commerce - 1 Federal - 1 PPI - 1 Ballard Power Systems - 1

Search resuls for: "Autolus Therapeutics"


2 mentions found


☆ 4 economic reports the market cares about most next week, including a fresh look at inflation
  + stars: | 2024-03-09 | by ( Zev Fima | ) www.cnbc.com   time to read: +8 min
Within the Club, we heard this week from Foot Locker on Wednesday, then from Costco and Broadcom on Thursday. The big economic data drop of the week arrived Friday with February's nonfarm payrolls report . The center of attention is Tuesday's February consumer price index report . On Thursday, the February produce price index is due out. ET: Producer Price Index 8:30 a.m.
Persons: FactSet, Locker, Foot Locker, February's nonfarm, Jerome Powell, he's, we'll, MANU, LEN, Jim Cramer's, Jim Cramer, Jim, Mostafa Bassim Organizations: Nasdaq, Dow Jones Industrial, Costco, Broadcom, Commerce, Federal, PPI, Ballard Power Systems, Fortrea Holdings, Casey's, Vail Resorts, MTN, Daniels, Midland, Kohl's Corporation, Kanzhun, Game Technology, Manchester United, Blade Air Mobility, Clover Health, Beauty Health, Energy Vault Holdings, PHX Minerals, Guild Holdings, Finance, Heron Therapeutics, ZIM Integrated Shipping Services, Arcos Dorados Holdings, ARCO, Petco, Wellness Company, Farms, Sonoma, WSM, ESS Tech, DICK'S Sporting, Inc, Futu Holdings, Bear, Autolus Therapeutics, III Apparel, Solo Brands, Weibo Corporation, Embraer, CNBC, Washington DC, Anadolu, Getty Locations: U.S, Asana, ASAN, Williams, Washington, United States
☆ Private equity acquires a taste for drug development
  + stars: | 2023-01-09 | by ( David Carnevali | ) www.reuters.com   time to read: +6 min
Jan 9 (Reuters) - Private equity firms that deemed drug development too risky for their liking in the past are increasingly investing in the sector, raising dedicated funds and coming up with deals that compensate them for the uncertainty involved. These deals are not structured as the leveraged buyouts that private equity firms are mostly known for. In most cases, the drug makers start paying the money back to the private equity firms when the drug is being developed, either by issuing equity, tapping cash on hand or borrowing. They also share a slice of the newly developed drug's revenue with the private equity firms once it's approved. Private equity firms also provide capital to spin out drugs into new companies.
0 next >>
Total: 2